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Background: Although persistent negative symptoms (PNS) are known to contribute significantly to poor
functional outcome, they remain poorly understood. We examined the heuristic value of various PNS definitions
and their respective prevalence in patients with first episode psychosis (FEP). We also contrasted those definitions
to the Proxy for the Deficit Syndrome (PDS) to identify deficit syndrome (DS) in the same FEP cohort.
Methods: One hundred and fifty-eight FEP patients were separated into PNS and non-PNS groups based on ratings
from the Scale for Assessment of Negative Symptoms (SANS). PNS was defined in the following ways: 1) having a
score of 3 or greater on at least 1 global subscale of the SANS (PNS_1); 2) having a score of 3 or more on at least 2
global subscales of the SANS (PNS_2); and 3) having a score of 3 or more on a combination of specific SANS
subscales and items (PNS_H). For all three definitions, symptoms had to be present for a minimum of six
consecutive months. Negative symptoms were measured upon entry to the program and subsequently at 1,2,3,6,9
and 12 months. Functional outcome was quantified at first assessment and month 12.
Results: PNS prevalence: PNS_1 (27%); PNS_2 (13.2%); PNS_H (13.2%). The prevalence of DS was found to be 3%
when applying the PDS. Regardless of the definition being applied, when compared to non-PNS, patients in the
PNS group were shown to have significantly worse functioning at month 12. All three PNS definitions showed
similar associations with functional outcome at month 12.
Conclusion: Persistent negative symptoms are present in about 27% of FEP patients with both affective and
non-affective psychosis. Although there has previously been doubt as to whether PNS represents a separate
subdomain of negative symptoms, the current study suggests that PNS may be more applicable to FEP when
compared to DS. Although all three PNS definitions were comparable in predicting functional outcome, we suggest
that the PNS definition employed is dependent on the clinical or research objective at hand.
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Growing evidence has suggested that negative symptoms in
psychotic disorders are intractable and associated with poor
functional outcome [1-3]. According to the most recent
National Institute of Mental Health (NIMH) consensus
statement, the negative symptom construct includes
blunted affect, anhedonia, alogia, asociality and avolition
[4]. However, broadly classifying negative symptoms into 5* Correspondence: martin.lepage@mcgill.ca
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which contribute to the heterogeneity of these symptoms
[5]. Thus, negative symptoms are further subdivided into
the following subtypes: 1) primary or idiopathic negative
symptoms, 2) secondary negative symptoms (caused by
positive symptoms, depression, or extrapyramidal symp-
toms), 3) deficit syndrome or deficit schizophrenia (DS),
believed to be a pathophysiological distinct disease within
schizophrenia and is diagnosed based on the presence of
primary enduring (minimum of 12 consecutive months)
[6], and 4) persistent negative symptoms (PNS) (primary
or secondary negative symptoms evident for 6 consecu-
tive months after the stabilization of a first episode of
psychosis) [5].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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cern given their resistance to treatment and persistence
throughout the illness, leading to poor prognosis. Varying
terminology and criteria have been used to describe and
identify PNS. Consequently, this lack of a consensus defin-
ition has yielded mixed results in terms of structural,
neuropsychological and functional correlates of PNS [for
review see [7]]. Recently, Buchanan suggested that the dur-
ation and severity of negative symptoms must be taken
into account when identifying PNS. The following criteria
were proposed: having at least moderate negative symp-
toms, having negligible positive, depressive or extrapyram-
idal symptoms, and clinical stability for an extended period
of time [5]. Empirical evidence on the proposed criteria for
PNS has been scant.
Some have suggested that PNS may represent a broader
concept than deficit syndrome [5,8]. Deficit syndrome,
which is proposed to identify a putatively more homo-
genous subgroup in schizophrenia, highlights the mani-
festation of prominent, primary and enduring negative
symptoms that are resistant to treatment. The criteria for
DS requires that negative symptoms of significant severity
be present for a minimum of one year, to have been
present at baseline (during periods of relative remission)
and are not secondary in nature [6]. Furthermore, patients
must meet the DSM criteria for schizophrenia spectrum
disorder [6]. Deficit syndrome is assessed using the
Schedule for the Deficit Syndrome (SDS), which is a
semi-structured interview measuring the persistence of 6
negative symptoms including restricted affect, diminished
emotional range, poverty of speech, curbed interests,
diminished sense of purpose, and diminished social drive
[6]. An individual must have moderate to severe scores
on at least 2 of these 6 symptoms. After the introduction
of the SDS, the Proxy for the Deficit Syndrome (PDS)
was introduced as a case identification for measuring
deficit symptoms [9]. This tool allows one to administer
common negative symptoms scales such as the Positive
and Negative Syndrome Scale (PANSS) or Brief Psychi-
atric Rating Scale (BPRS) and to apply the PDS formula
to obtain a score determining whether the patient meets
the criteria for DS. The PDS is defined as the sum of the
scores for Anxiety, Guilt Feelings, Depressive Mood and
Hostility items from the scales subtracted from the score
of Blunted Affect [9].
Unlike DS which is quantified using the SDS [6], nega-
tive symptom severity for PNS can be measured using any
validated negative symptom scale. According to the NIMH
consensus statement [4] the Scale for the Assessment of
Negative Symptoms (SANS) [10] has the most extensive
coverage. Other scales such as the PANSS [11] are also
widely used, but do not provide as much detail on negative
symptoms as the SANS. However, some concerns regar-
ding these scales have been raised. For instance, earlyevidence suggests that some items from the SANS includ-
ing, “poverty of content of speech” and “inappropriate
affect” represent a disorganization dimension rather than
negative symptoms of schizophrenia [12]. Exploratory and
confirmatory factor analytical studies identified three
underlying factors in the negative symptoms construct
including 1) affective flattening 2) avolition/apathy and
anhedonia/asociality and 3) inattention/alogia [13-15].
Concordant factors have been documented in a FEP co-
hort [16]. These factors are incorporated into the SANS
[10]. However, there is now a general consensus that in-
attention may not be conceptually related to negative
symptoms [8,17,18]. Furthermore, some findings are sug-
gestive of interrelated yet separate subdomains of negative
symptoms in schizophrenia including, 1) diminished ex-
pression, composed of affective flattening and poverty of
speech, and 2) amotivation, consisting of avolition/apathy
and anhedonia/asociality [4,8,17]. Similarly, in patients
with DS, a principle component analysis using the Sched-
ule for Deficit Syndrome indicated that DS is best
described by two factors including avolition and reduced
emotional expression [19]. It is possible that this multidi-
mensionality within negative symptoms is relevant not
only to chronic schizophrenia but to FEP patients with
PNS as well; this has not been investigated.
The lack of “gold standard” for PNS has brought up
some major concerns [4,20-22]. Also, studies have not em-
ployed comparable criteria to identify PNS. For instance,
while one study included patients in the “negative symptom
group” if they scored 2 or more on a minimum of 1 global
SANS subscales [23], others have used a score of 3 or more
[3]. In addition, some have also applied criteria that involve
having clinically significant symptoms (score ≥3) on a mini-
mum of 2 global items of the SANS [24].
Given this variability, it is likely that using different cri-
teria for identifying PNS will yield mixed results. Hence,
there is a need for PNS criteria that are clinically useful in
identifying PNS. The first episode of psychosis may be a
critical time to identify individuals with PNS in order to
potentially influence these symptoms through more fo-
cused intervention such as intensive psychosocial inter-
ventions. Further, given the lack of consensus definition
for PNS, its prevalence in FEP using well-defined criteria
remains unknown. The main objective of this paper was
to examine the heuristic value of various PNS definitions
and their respective prevalence in patients with first epi-
sode psychosis. Second, given that DS also represents a
subgroup of patients with enduring negative symptoms,
we wanted to contrast the PNS definitions with the proxy
definition for deficit syndrome in a FEP cohort. To sub-
stantiate the clinical predictive validity of the abovemen-
tioned definitions, all were explored in association with
patient function followed over a 12-month period in a co-
hort of first-episode of psychosis patients. We hypothesize
Hovington et al. BMC Psychiatry 2012, 12:224 Page 3 of 11
http://www.biomedcentral.com/1471-244X/12/224that patients meeting the PNS criteria will have poorer
functioning than those not meeting the criteria [25-27].
Methods
Subjects
All patients were part of a longitudinal naturalistic out-
come study of first-episode psychosis and were recruited
and treated through the Prevention and Early Intervention
Program for Psychoses (PEPP-Montreal), a specialized
early intervention service with integrated clinical, research,
and teaching modules, at the Douglas Mental Health
University Institute in Montreal, Canada. Individuals aged
14 to 35 years from the local catchment area suffering
from either affective or non-affective psychosis that had
not taken antipsychotic medication for more than one
month and with an IQ higher than 70 were consecutively
admitted to the program as either in- or out-patients. For
complete program details see Malla et al. [28] or visit
http://www.douglasresearch.qc.ca/pages/view?section_id=
165. Patients were diagnosed according to DSM-IV criteria
using the Structured Clinical Interview for DSM-IV
(SCID-IV) [29]. Written informed consent was obtained
from all participants. Research protocols were approved by
the Douglas Institute Human Ethics Review Board.
Clinical assessment
For all subjects who met the inclusion criteria, an initial
assessment was conducted on average, within one month
after admission (in days; mean=22.7, s.d.= 8.6, range=8.3-
54.8). At the initial assessment the following data were
acquired: education level (number of school years com-
pleted), Full Scale IQ with the Wechsler Adult Intelligence
Scale [30], parental socio-economic status (SES) with the
Hollingshead two-factor index [31], The Premorbid Ad-
justment Scale (PAS) [32], and handedness [33]. Negative
and positive symptoms were assessed with the Positive
and Negative Symptoms Scale (PANSS) as well as the
SANS [10] and SAPS [34], respectively. The domain of at-
tention in the SANS scale was not included in our ana-
lyses. Evaluators at PEPP established an ICC of 0.74 on
the SAPS and 0.71 on the SANS; all raters participated in
inter-rater reliability sessions at least once a year to avoid
rater drift (i.e. raters must maintain consistency with
themselves as well as with other raters). Depressive symp-
toms were assessed with the Calgary Depression Scale for
Schizophrenia (CDSS) [35] and extrapyramidal symptoms
with the Extrapyramidal Symptoms Rating Scale (ESRS)
[36]. If prescribed, based on the ESRS and attending phy-
sician’s discretion, type and dose of anticholinergic taken
were recorded. The type and dosage of antipsychotics taken
were also recorded and subsequently converted into chlor-
promazine equivalents [37]. As part of the longitudinal
study, severity of positive, negative, depressive and extrapyr-
amidal symptoms was evaluated at initial assessmentand 1,2,3,6,9 and 12 months later, using the SAPS, SANS,
CDS and ESRS, respectively.
The period of “prodrome”, calculated through the Cir-
cumstances of Onset and Relapse Schedule (CORS) inter-
view which is based on the Interview for the Retrospective
Assessment of Schizophrenia (IRAOS) [38], was defined
as the time between the onset of any psychiatric symp-
toms and the onset of the presenting psychotic episode.
From this interview, such variables as duration of un-
treated psychosis (DUP), duration if untreated illness
(DUI), pre-morbid functioning levels, and socio-economic
status are obtained. Psychiatric symptoms refer to symp-
toms indicating a behavioural change such as anxiety, de-
pression, suicidal ideation, or social withdrawal as well as
sub-threshold psychotic symptoms such as suspiciousness
and odd ideas and behaviour and do not include develop-
mental disorders. Duration of untreated psychosis was cal-
culated as time from the first episode to the date of entry
into the program. Finally, DUI was calculated as the time
between the first ever onset of any psychiatric symptoms
to the time of adequate treatment, as above [39]. Duration
of untreated illness included periods of psychiatric symp-
toms not necessarily contiguous with the psychotic epi-
sode and interspersed with relatively healthy periods. All
other demographic data were obtained through the same
interview.
Method for identifying persistent negative symptoms
Upon completing 12 months of the treatment program,
clinical data were analyzed and PNS definitions were ap-
plied based on data collected from the first assessment,
months 1,2,3,6,9 and 12. Negative symptoms were required
to be present after the initial stabilization of symptoms
(month 3) and maintained for 6 consecutive months
(months 6, 9 and 12) with at least a moderate severity as
measured on a validated scale [5]. Although 6 months has
often been employed as the point of initial stabilization
[24], our previous findings along with recent data in FEP,
suggests a decrease of acute psychotic symptoms and an
initial stabilization period closer to 3 months [40-43]. In
addition, factor analytical studies have suggested that some
items of the SANS including, “poverty of content of
speech” and “inappropriate affect” poorly correlate with
the scale [13,15]. Hence, as suggested by Malla et al. [3], if
the global rating on “affective flattening” or “alogia” was
based entirely as a result of items “inappropriate affect” or
“poverty of content of speech”, respectively, such patients
were not included in the PNS group.
All subjects with secondary negative symptoms were
excluded from analyses. Patients were required to have a
global rating of mild (2) or less on all positive symptoms
as measured by the Scale for the Assessment of Positive
Symptoms (SAPS) [34], a total score of 4 or less on the
Calgary Depression Scale for Schizophrenia (CDSS) [35],
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mild to require treatment with anticholinergic medication
based on the ESRS [36].
All of the above mentioned criteria had to be maintained
for a period of at least 6 consecutive months (specifically
between month 6 and 12 after admission). In addition to
having negative symptoms for 6 consecutive months, pa-
tients with affective or non-affective psychosis were also
required to have clinically significant negative symptoms
(“clinically significant” symptoms were considered to be
moderate to severe scores on SANS items, or scores of 3
or greater) on the SANS scale at month 3.
Lastly, three PNS definitions applied in various studies
for identifying persistent negative symptoms during a
12-month longitudinal study and the PDS for identifying
DS were explored [3,9,24]:
Persistent negative symptom:
1. PNS_1: a score of 3 or more on at least 1 global item
of the SANS [3].
2. PNS_2: a score of 3 or more on at least 2 global
items of the SANS [24].
3. PNS_H: a SANS score of 3 or more on either one or
both of the following subdomains as previously
described by Foussias and Remington [8]:
1) Diminished expression (must have a score of 3 or
more for both affective flattening and poverty of
speech) and/or 2) Amotivation (must have a score of
3 or more for both avolition/apathy and anhedonia/
asociality).
Deficit syndrome:
1. DS (using PANSS): PDS Score = Blunted Affect (n1) –
[Anxiety (G2) + Guilty Feelings (G3) + Depressed Mood
(G6) + Hostility Items (P7)]. In order to be classified as
meeting the criteria for DS, patients were required to have
a score greater than two on the PDS [9]. Similarly to PNS,
this criterion had to be met at months 3,6,9 and 12. In
other words, the proxy definition was not employed for 12
consecutive months, as it is required. Given that this study
examined a group with FEP, retrospectively assessing DS
would have begun at the first episode when symptoms are
not yet stable.
Statistical analysis
All analyses were conducted using PASW version 18
(SPSS, Chicago, IL) and were two-tailed with a critical
p-value of 0.05. Group differences with regard to the first
assessment variables for DUP, DUI, length of prodrome
and SOFAS scores were analyzed using independent
t-tests. The following clinical characteristics were not nor-
mally distributed (Shapiro-Wilks W test): DUP, DUI
prodrome and CDSS scores. Prodrome, DUI and CDSSscores were normalized using square root transformations,
while DUP was normalized using a logarithmic transform-
ation. Group differences were also compared at several
time points (first assessment, months 3 and 12) for clinical
symptoms including SANS, SAPS and CDSS total scores
as well as for SOFAS scores using independent t-tests. In-
dependent t-tests were also used to compare group differ-
ences between PNS and non-PNS for age, DUI, DUP and
prodrome. The prevalence of PNS in patients with FEP
was determined at month 12. Patients were categorized
into PNS or non-PNS (and further subdivided according
to which PNS criteria they met). In addition, patients who
met the PDS criteria according to the previously published
cutoff (≥2) [9] were categorized in the DS group. To deter-
mine the association between PNS and function, repeated
measures ANOVA were used to examine group differ-
ences between PNS definitions (each definition separately)
and SOFAS score (first assessment, month 12) used as the




Data from a cohort of 280 FEP patients treated between
2003 and 2009 were collected. Of these, 100 had missing
clinical data between months 3 and 12 due to one or more
missed assessments. These subjects were excluded from
further analyses since they could not be classified as PNS
or non-PNS. Of note, no differences in age, DUP, DUI or
prodrome were found between included patients and
excluded patients due to missing data. Sixty-six of the 180
FEP patients had a score greater or equal to 3 on at least
one SANS subscales. Twenty-two out of these 66 patients
were excluded because of secondary negative symptoms
(15 for moderate positive symptoms with SAPS score >2,
six had clinically significant depressive symptoms, 3 for
extrapyramidal symptoms and 1 for substance-induced
symptoms (Note: two patients met the criteria for more
than one secondary negative symptom). Hence, 44 FEP
patients were included in the PNS group for analyses.
Figure 1 illustrates patient classification for the current
study.
See Table 1 for results of patient demographics and clin-
ical characteristics. Patients with PNS did not differ from
patients without PNS in age, gender, DUI, DUP, and pro-
drome. The PNS group had significantly worse function-
ing at first assessment and at month 12 when compared
to non-PNS groups. The PNS group had significantly
worse negative symptoms scores than non-PNS at all time
points. The PNS and non-PNS groups had similar scores
on both positive symptom and depression scales. Mean
negative and positive symptom scores for PNS and non-
PNS were compared at each assessment and are presented
in Figure 2A and B. Similar to previous findings [40-43],
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by the third month of treatment. Individual domains were
explored (Figure 2C and D). The frequency of patients
with PNS who met the criteria (≥3) for any of the 4
domains SANS as well as the mean score of the PNS
group for each domain was explored. Patients meeting the
criteria for PNS_1 had higher levels of avolition/apathy as
well as anhedonia/asociality both in terms of meeting the
PNS criteria due to these domains as well as having higher
mean scores in these domains. Primary diagnoses for all
patients in the PNS groups are found in Table 2. The ma-
jority of patients in the PNS_1 group were diagnosed with
schizophrenia (paranoid) (20.5%) or schizophrenia (undif-
ferentiated) (20.5%). On the other hand, a greater num-
ber of patients in the PNS_2 and PNS_H groups were
diagnosed with schizoaffective disorder or schizophrenia
(undifferentiated).
Prevalence and associations with functional outcome
PNS_1 definition Forty- four patients (27.8%) were iden-
tified with PNS and 114 (72.2%) were not. This liberal def-
inition showed the highest prevalence of PNS compared
to the other two definitions. The repeated measures
ANOVA revealed a significant main effect of time
(F1,82=71.762, p<0.001) and a significant main effect of
group (F1,82=10.065, p=0.002). Figure 3 illustrates SOFAS
scores over time for PNS_1, PNS_2 and non-PNS patients.
A significant [time x group] interaction (F1,83=4.117,
p=0.046) was also observed. Further analyses revealed
SOFAS scores for patients with PNS were significantlyFigure 1 Classification of FEP patients based on negative symptoms.lower at both initial assessment (F1,125=4.343, p=0.039)
and at month 12 (F1,109=17.328 p<0.000) compared to
patients without PNS. Paired t-tests revealed that PNS_1
(t23=−4.335, p<0.000) and non-PNS (t59= −9.414, p<0.000)
both significantly improved over time. A score of 60 or
greater on the SOFAS is considered to represent good
functioning [44,45]. Interestingly, only the non-PNS group
had a mean score greater than 60 on the SOFAS scale at
month 12. See Table 1 for SOFAS scores.
PNS_2 definition Twenty-one patients (13.3%) met the
criteria for PNS_2, while 137 did not (86.7%). Similarly to
the PNS_1 definition, repeated measures ANOVA re-
vealed a significant main effect of time (F1,82=28.525,
p<0.001) and a significant effect of group (F1,82=14.661,
p<0.001). There was no significant [time x group] inter-
action (F1,82=2.956, p=0.089) observed. Further analyses
revealed that patients with PNS had significantly worse
functioning at the initial assessment (F1,126= 6.669,
p=0.011) and at month 12 (F1,103 =20.981, p<0.001) than
patients in the non-PNS group. Paired t-test revealed that
PNS_2 (t9=−2.239, p<0.052) and non-PNS (t73= −10.072,
p<0.000) both significantly improved function over time.
Similarly to the PNS_1 definition, the mean SOFAS score
for the PNS_2 group was not greater than 60, which is
considered to be “poor functioning”.
PNS_H definition Twenty-one patients (13.3%) met the
criteria for PNS_H, while 137 (86.7%) did not. Repeated
measures ANOVA revealed a significant main effect of
time (F1,82=28.525, p<0.001) as well as a significant effect
Table 1 Demographics and clinical characteristics of PNS
cohort (as per PNS_1 criteria)
PNS Non-PNS F, χ 2 or t,
(n=44) (n=114) p-value
Age at entry, years 22.0±4.0 22.9±4.1 t=1.29, .195
Gender (m/f) 30/14 82/32 χ 2 =0.216, .697
DUI, weeks b 286.9±273.3 254.7±260.1 t=−0.679, .498
DUP, weeks b 42.3±56.3 47.7±110.4 t=0.305, .761
Prodromal period b 104.3±178.3 90.1±159.2 t= −0.478, .634
SOFAS
1st assessment 40.0±12.7 47.0±14.5 t=2.403, .018*
Month 12 54.2±14.9 67.5±14.4 t=4.233, <.001*
SANS Total
1st assessment 40.0±17.6 27.5±15.5 t=−4.335, <.001*
Month 3 33.1±13.0 18.6±11.5 t=−6.594, <.001*
Month 12 33.7±14.5 15.6±11.1 t=−7.961, <.001*
SAPS Total
1st assessment 31.2±12.4 31.6±13.7 t=−0.153, .878
Month 3 6.7±7.2 4.2±5.4 t=−2.320, .047*
Month 12 6.6±6.9 6.8±12.4 t= .103, .918
CDSS Total
1st assessment 5.3±4.8 4.9±5.3 t=−0.347, .729
Month 3 1.9±3.0 2.0±3.1 t=0.296, .768
Month 12 1.6±2.8 1.5±2.9 t=−0.314, .754
DUP= duration of untreated psychosis (from first episode to date of entry to
PEPP); DUI=duration of untreated illness; SANS= Scale for the Assessment of
Negative Symptoms; SAPS= Scale for the Assessment of Positive Symptoms;
SOFAS = Social and Occupational.
a Hollingshead Parental Socio-Economic Status, in which 1 = highest and
5 = lowest.
b Analyses were made with transformed data but values are presented in
raw form.
Note: Secondary negative symptoms were removed from analyses.
Data presented as mean ± SD ( χ 2or t, p-value).
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group] interaction was found (F1,82=2.956, p=0.089).
Group comparisons with a one-way ANOVA revealed sig-
nificantly worse SOFAS scores for the PNS group at the
initial assessment (F1,126=6.669, p=0.001) and at month 12
(F1,102=20.981, p<0.001). Paired t-tests revealed that both
PNS (t9=−2.239, p<0.052) and non-PNS (t73= −10.072,
p<0.000) groups improved in function over time. Only
patients not meeting the PNS_H criteria achieved good
functioning.
Prevalence of DS in FEP Only five FEP patients (3%)
met the criteria for deficit syndrome according to the
proxy definition. All five patients in this group had an ini-
tial diagnosis of schizophrenia (disorganized, paranoid or
undifferentiated).
Furthermore, as previously mentioned, when compared
to any of the 3 PNS groups, only the cohort with non-PNSpatients achieved a mean score of “good functioning”
according to the SOFAS scale. Due to missing data, only
140 of the patients obtained a SOFAS score at month 12
(31 from the PNS cohort and 109 from the non-PNS co-
hort). However, of those with available SOFAS scores at the
12 month follow-up, 61% of patients from the PNS_1 group
(19/31) were considered “poorly functioning” whereas only
26% of non-PNS patients (28/109) were “poor functioning”.
Interestingly, of the 39% of PNS patients (12/31) with “good
functioning”, 83% (10/12) met the PNS criteria for PNS_1
only and not PNS_2 or PNS_H.
Supplementary analysis of the PNS_1 group
To further delineate whether a stringent PNS definition is
more clinically significant, “liberal” and “stringent” sub-
groups were formed. More specifically, the “stringent”
group was formed of both PNS_2 and PNS_H groups com-
bined. To obtain a “clean” PNS_1 group, specific patients in
the PNS_1 group were extracted and re-named as the “lib-
eral” group. The “liberal” subgroup consisted of patients
who only met the criteria for PNS_1 only and not PNS_2
and/or PNS_H (i.e. all patients who met the criteria for
PNS_2 or PNS_H automatically also met the criteria for
PNS_1, but not all patients in the PNS_1 group met the cri-
teria for PNS_2 or PNS_H). Of the 44 patients in the
PNS_1 group, 23 patients met the “liberal” criteria. There-
fore, 21 patients were left in the “stringent” group. Using
the “liberal” group, repeated measures ANOVA were used
to establish whether isolating this “liberal” group would im-
pact the previous results with the entire PNS_1 group.
Scores from the SOFAS scale were used as within subject
variables (first assessment, month 12) and group (liberal,
stringent) as the between subject variable. A main effect of
time was observed (F 1,82=48.089, p<0.001). However, al-
though there was a significant [time x group] interaction
using the entire PNS_1 cohort, isolation of the “liberal”
group from this definition failed to reveal any significant
[time x group] interactions (F1,82=0.879, p=0.351).
Discussion
Main findings
The main findings of this study suggest the prevalence of
PNS in FEP varies depending on the definition being ap-
plied. More specifically, the prevalence of PNS was shown
to be between 13 and 27%. Patients identified as having
PNS (regardless of the definition) were consistently shown
to have poorer functional outcome at month 12. However,
all three PNS definitions demonstrated similar associations
with functional outcome. Both PNS and non-PNS cohorts
improved function over a 1-year period; however, the PNS
group never met the criteria for “good functioning” accord-
ing to mean SOFAS scores. Interestingly, when patients
who met the criteria solely for our PNS_1 definition were





Figure 2 A) SANS total scores from first assessment to month 12; B) SAPS total scores from first assessment to month 12 *= p<0.001;
C) Frequency of patients that met PNS_1 criteria for the 4 subdomains of the SANS; D) Mean scores for the 4 subdomains of the SANS
for patients meeting the PNS_1 criteria. N= 158 (44 PNS and 114 non-PNS) *= Domain was significantly different than all the other three SANS
domains. 1st= First Assessment. Note: SANS total scores do not include the “Attention” domain.
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year follow-up. The majority of patients met the PNS cri-
teria due to clinically significant global scores on either the
Avolition/Apathy or Anhedonia/Asociality domains of the
SANS scale. Lastly, applying the proxy definition to identify




Schizophrenia- Paranoid 9 (20.5)
Schizophreniform 1 (2.3)
Schizoaffective 8 (18.2)
Schizophrenia- Undifferentiated 9 (20.5)
Bipolar I – With psychotic features 5 (11.4)
Major Depression – With psychotic features 2 (4.5)
Bipolar I – Manic with psychotic features 2 (4.5)
Bipolar I – Depressed recent episode 1 (2.3)
Psychosis NOS 3 (6.8)
Data presented as frequency (percentage).Can the deficit syndrome criteria be applied in first
episode psychosis?
The prevalence of primary enduring negative symptoms,
or deficit syndrome in first episode patients has been esti-
mated to be around 15% [46]. However, when applying
the PDS to identify individuals with DS in a FEP cohort,PNS_2 PNS_H PDS
N=21 N=21 N=5
2 (9.5) 2 (9.5) 1 (20.0)
3 (14.3) 3 (14.3) 1 (20.0)
- - -
7 (33.3) 7 (33.3) -
6 (28.6) 6 (28.6) 3 (60.0)
- - -
1 (4.8) 1 (4.8) -
1 (4.8) 1 (4.8) -
1 (4.8) 1 (4.8) -
- - -
Figure 3 Mean SOFAS scores at the first assessment and month 12 follow-up for patients with and without PNS.
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http://www.biomedcentral.com/1471-244X/12/224the current findings suggested a prevalence of 3% when
compared to 13-27% using the PNS criteria. Initially, the
PDS was validated with a chronic schizophrenia out-
patient cohort [9]. While DS only applies to schizophrenia
spectrum disorder, the current study demonstrates that
prominent and enduring negative symptoms or PNS im-
pacting functional outcome include FEP patients with sev-
eral primary diagnoses including schizoaffective, bipolar I
with psychotic features and major depression with psy-
chotic features. Accordingly, this may suggest that this
subgroup of negative symptoms is relevant not only to
patients with a diagnosis of schizophrenia. In fact, a diag-
nosis of schizoaffective disorder fell within the top three
most common diagnoses for any of the three PNS defini-
tions. It may be possible that when compared to DS, PNS
is a more appropriate subgroup found in FEP patients
with both affective and non-affective diagnoses.
It has been suggested that affective flattening and alogia
(poverty of speech) are strongly associated and represent
the “core negative symptoms” contributing to poor func-
tional outcome [3,16,22]. In DS, affective flattening was
previously shown to be significantly more severe in DS
when compared to non-DS. The PDS case identification
tool requires affective items to be subtracted from the
blunted affect score of the PANSS or BPRS scales. In FEP
patients, flat affect and alogia have not always been shown
to be the most prominent negative symptoms [47]. Simi-
larly, the results of the current study demonstrated low
levels of the “diminished expression” subdomain of nega-
tive symptoms in the PNS cohort. It is plausible that these
low levels of affective flattening in FEP greatly impact the
prevalence of DS. More recently, the PDS formula wasfurther altered to include both blunted affect and poverty
of speech items [48]. Adding this second negative symp-
tom would possibly further decrease the prevalence of DS
in chronic schizophrenia and more so in a FEP population.
Thus, in a group of FEP patients PNS, blunted affect and/
or alogia do not seem to be the driving forces of these per-
sistent symptoms and this may elucidate why the preva-
lence of DS was lower than previously documented [9].
Influence of persisting negative symptoms on functional
outcome
Similar to past findings in DS showing poorer functioning
in DS when compared to non-DS [49], our results showed
worse functional outcome at month 12 regardless of the
PNS definition being applied. Several functional outcomes
appear to be impacted by negative symptoms including
psychosocial functioning, recreation, relationships, and
occupational functioning [27,50,51]. An investigation by
Milev et al. [27] assessed whether or not the severity of
negative symptoms could predict functional outcome. In-
deed, in comparison to positive and disorganized symp-
toms, negative symptom severity was shown to have the
greatest predictability for poor psychosocial functioning.
Concordantly, the current results demonstrated that ap-
plying the PNS_1 definition was sufficient to identify FEP
patients with PNS at risk of poor functioning 12 months
after entry into a FEP program.
Initial descriptions of schizophrenia included Kraepelin’s
observation of avolition being prominent as a key symp-
tom [52]. Accordingly, several studies have demonstrated
more severe negative symptoms in the SANS subscales of
anhedonia/asociality and avolition/apathy [16,25,53,54].
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http://www.biomedcentral.com/1471-244X/12/224These SANS domains have also been associated with poor
functional outcome, suggesting that the putative role of
negative symptoms on functional outcome may be largely
influenced by these domains. Similarly, our results showed
greater mean scores on both these SANS domains as well
as a greater number of FEP patients meeting the PNS cri-
teria due to these SANS domains. Thus, the role of these
two domains, which has been referred to as the “amotiva-
tion” subdomain of the SANS may play a pivotal role in
PNS and its association with poor functional outcome [8].
Individually, the apathy domain of negative symptom-
atology has also been shown to contribute to poor func-
tioning at year 1 [55,56]. However, given the content
overlap observed when quantifying apathy and measu-
ring functional outcome [57], this may have some influ-
ence on their relationship due to their tautology. This is
a concern raised by previous authors [58] and may have
been a limitation in the current study. Nonetheless, im-
proving social and occupational functioning is a major
objective in the treatment of FEP patients and a step to-
wards recovery. Given the results of the current study, it
may be more beneficial to identify individuals with PNS
who are at a greater risk of functional decline by apply-
ing more stringent criteria. This will help build a stron-
ger foundation for a more concise PNS definition.
Secondary negative symptoms
Nineteen patients with PNS were removed from our ana-
lyses due to secondary negative symptoms. Secondary
negative symptoms are thought to have a distinct etiology
from that of primary negative symptoms [59]. Thus, to
increase homogeneity of a cohort it is preferable to cha-
racterize both features of negative symptoms. However,
investigations have not always made this distinction
[60,61] - partly due to the difficulty in distinguishing pri-
mary from secondary negative symptoms [62-64]. It was
suggested that secondary negative symptoms not respon-
ding to treatment should be included in the criteria for
PNS [5]; albeit, the criteria proposed requires one to have
minimal or no positive, depressive and extrapyramidal
symptoms. It may be possible that patients with enduring
secondary negative symptoms (due to positive symptoms
not responding to treatment) may benefit specifically from
interventions targeting PNS such as transcranial magnetic
stimulation (TMS) [65-68]; however, this has not been
empirically substantiated. Future studies should investi-
gate the role these secondary negative symptoms have in
PNS in order to provide a stronger rationale for including
or excluding them from PNS.
Characterization of the PNS cohort
Previous findings have documented longer DUP in
patients with more prominent and enduring negative
symptoms [3,24,63]. In a first episode cohort assessedduring the first year of illness, DUP was also shown to
predict PNS [3]. Furthermore, some studies have proposed
that negative symptoms appear prior to the onset of posi-
tive symptoms, occurring in the prodromal period [69,70].
The current study did not replicate these findings; no sig-
nificant group differences were found for DUP or length
of the prodromal period. Regardless of the lower DUP and
prodromal period, patients still met the criteria for PNS
suggesting that there may be other factors contributing to
PNS. Furthermore, at the first assessment, our PNS group
had significantly worse negative symptoms when com-
pared to the non-PNS group while positive symptoms
were similar between groups. This may support the idea
that more severe negative symptoms occurring earlier on
have a significant contribution to residual negative symp-
toms. Hence, clinically significant negative symptoms at
the onset of psychosis may be a strong indicator of PNS.
Choosing a PNS definition
Choosing which PNS definition to employ may be
dependent on the research question being asked. From an
intervention perspective, the number of patients needs to
be maximized to have a stronger conclusion determining
the efficacy of a given intervention. Hence, applying our
PNS_1 definition may be more appropriate. Interestingly,
all patients who met the criteria for PNS_2 also met the
criteria for either of the two domains of the hybrid defin-
ition (diminished expression or amotivation). Future re-
search should focus on identifying the neurobiological and
physiological determinants of PNS_1 and PNS_2 in order
to determine whether they are distinct or share simila-
rities. Furthermore, as suggested by Buchanan [5], it may
be beneficial to include patients with persistent secondary
negative symptoms that have not responded to treatment
when employing this particular research question.Limitations
Some studies have suggested that a follow-up of two or
more years may be more appropriate when exploring
symptoms in FEP [27,71]. Our study had a one-year follow
up and this may have been a limitation in terms of under-
standing the trajectory of PNS. A 5-year follow up may
have helped us better delineate the course of PNS in our
FEP cohort.
Conclusions
Persistent negative symptoms are present in about 27% of
FEP patients. Applying either of our PNS definitions for
identifying PNS is a feasible method for identifying
patients with PNS at risk of poor functioning. However,
the definition being employed should depend on the re-
search objectives. Given the association between PNS and
poor functional outcome 12 months after entry into our
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http://www.biomedcentral.com/1471-244X/12/224treatment program, it is highly recommended to identify
PNS within the first year of illness. When compared to
the PDS, using a PNS criteria may be more applicable to a
FEP cohort to identify enduring negative symptoms. As it
has been stated ad nauseam, we need to standardize how
to define PNS in order to obtain a better understanding of
these symptoms. Further longitudinal, rather than cross-
sectional studies on the development and treatment of
PNS in a FEP population are warranted.
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